Clinical Positron Emission Tomography/Computed Tomography: Quarter-Century Transformation of Prostate Cancer Molecular Imaging

David C Chen; Siyu Huang; James P Buteau; Raghava Kashyap; Michael S Hofman

doi:10.1016/j.cpet.2023.12.011

Clinical Positron Emission Tomography/Computed Tomography: Quarter-Century Transformation of Prostate Cancer Molecular Imaging

PET Clin. 2024 Apr;19(2):261-279. doi: 10.1016/j.cpet.2023.12.011. Epub 2024 Jan 9.

Authors

David C Chen¹, Siyu Huang², James P Buteau¹, Raghava Kashyap¹, Michael S Hofman³

Affiliations

¹ Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.
² Department of Surgery, The University of Melbourne.
³ Prostate Cancer Theranostics and Imaging Centre of Excellence, Molecular Imaging and Therapeutic Nuclear Medicine, Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia. Electronic address: michael.hofman@petermac.org.

PMID: 38199918
DOI: 10.1016/j.cpet.2023.12.011

Abstract

Although positron emission tomography/computed tomography (PET/CT) underwent rapid growth during the last quarter-century, becoming a new standard-of-care for imaging most cancer types, CT and bone scan remained the gold standard for patients with prostate cancer. This occurred as 2-fluorine-18-fluoro-2-deoxy-d-glucose was perceived to have a limited role owing to low sensitivity in many patients. A resurgence of interest occurred with the use of fluorine-18-sodium-fluoride PET/CT as a replacement for bone scintigraphy, and then choline, fluciclovine, and dihydrotestosterone (DHT) PET/CT as prostate "specific" radiotracers. The last decade, however, has seen a true revolution with the meteoric rise of prostate-specific membrane antigen PET/CT.

Keywords: PET; PET/CT; PSMA; Prostate-specific membrane antigen; Radiopharmaceuticals; Radiotracers.

Publication types

Review

MeSH terms

Fluorine Radioisotopes
Gallium Radioisotopes
Humans
Male
Molecular Imaging
Positron Emission Tomography Computed Tomography* / methods
Prostatic Neoplasms* / diagnostic imaging

Substances

Fluorine-18
Fluorine Radioisotopes
Gallium Radioisotopes